Currently held
- Agent 4 — Dip Buyer (Frozen)long1 sh @ $775.97 · stop $713.89-$26.60 unrealized
MCK
Mckesson CorporationHealth Careinsider_universeLast close $767.31Jun 28, 2026
Day +0.50%
Everything we've seen
- ·Jun 29, 3:49 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 3:34 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 3:19 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 3:05 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 2:49 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 2:34 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 2:19 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 2:19 PMstreamnews
3 Reasons We Love McKesson (MCK)
Over the past six months, McKesson’s shares (currently trading at $763.33) have posted a disappointing 8.1% loss, well below the S&P 500’s 6.8% gain. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
- ·Jun 29, 2:04 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 1:49 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 1:34 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ❖Jun 29, 1:30 PMnewsvia finnhub
3 Reasons We Love McKesson (MCK)
Over the past six months, McKesson’s shares (currently trading at $763.33) have posted a disappointing 8.1% loss, well below the S&P 500’s 6.8% gain. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
- ·Jun 29, 1:19 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 1:03 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 12:48 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 12:33 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 12:18 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 12:03 PMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ·Jun 29, 11:48 AMstreamnews
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ❖Jun 27, 5:05 PMnewsvia finnhub
Financial Institutions Boost Dividends In June As 16 Companies Ready To Increase Payouts In July
Dividend increase predictions for dividend-growth stocks: banks boosted payouts after Fed stress tests; BAC and Clorox next.
- ❖Jun 26, 1:55 PMnewsvia finnhub
Dividend Champion, Contender, And Challenger Highlights: Week Of June 28
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read it here.
- ❖Jun 25, 5:15 PMnewsvia finnhub
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.
- ❖Jun 24, 9:00 AMnewsvia finnhub
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- ❖Jun 24, 8:00 AMnewsvia finnhub
McKesson Corporation Announces First Quarter Fiscal 2027 Earnings Release Date
IRVING, Texas, June 24, 2026--McKesson Corporation (NYSE: MCK) will release its first quarter fiscal 2027 financial results after market close on Wednesday, August 5, 2026. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.
- ❖Jun 24, 3:22 AMnewsvia finnhub
TCW Concentrated Large Cap Growth Fund Q1 2026 Portfolio Activity
We believe McKesson's current share price does not adequately reflect the longer-term cash flow generation potential of the business.
- ❖Jun 23, 7:53 PMnewsvia finnhub
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.
- ❖Jun 23, 3:41 PMnewsvia finnhub
McKesson Selects Moore, Oklahoma for a State-of-the-Art Regional Distribution Center Positions Cleveland County as a National Healthcare Supply Chain Hub
Today, the Oklahoma Department of Commerce and the Cleveland County Economic Development Coalition announced that announced that McKesson Corporation, a Fortune 100, U.S. based company that serves as a logistical and operational backbone of the healthcare system to help ensure patients can access medicines, has selected Moore, Oklahoma as the location for a highly automated regional distribution facility at the North Moore Industrial Park. The new facility will replace an existing distribution c
- ?Jun 23, 10:35 AMdecisionconsidered
Agent 7 — Day Trader — analyze: fail
Claude analysis failed: Anthropic 529: {"type":"error","error":{"type":"overloaded_error","message":"Overloaded"},"request_id":"req_011CcLMj6GYJ3jt8QiD3XAxG"}
- !Jun 23, 10:35 AMsignal
Agent 7 — Day Trader — analyze_failed
- ❖Jun 23, 8:00 AMnewsvia finnhub
McKesson ideaShare 2026 Fuels Momentum for Independent Pharmacies
IRVING, Texas, June 23, 2026--Last week, McKesson Corporation hosted McKesson ideaShare 2026, the company’s annual event for independent community pharmacies, in Denver, Colorado.
- ❖Jun 19, 1:10 PMnewsvia finnhub
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.
- ❖Jun 19, 8:36 AMnewsvia finnhub
CAH Stock Up Nearly 8% YTD: Will the Uptrend Continue in the Rest of 2026?
Cardinal Health has gained nearly 8% in 2026 as specialty pharma growth, rising EPS, and expanding healthcare services fuel investor optimism.
- ❖Jun 18, 5:50 PMnewsvia finnhub
McKesson (MCK) Stock Sinks As Market Gains: Here's Why
McKesson (MCK) closed the most recent trading day at $750.63, moving 3.74% from the previous trading session.
- ❖Jun 18, 12:49 PMnewsvia finnhub
COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell?
COR shares are down 18% YTD, but rising EPS guidance, specialty pharma growth and strategic expansion could make this pullback worth watching.
- ❖Jun 17, 9:35 AMnewsvia finnhub
7 Health Care Stocks With Whale Alerts In Today's Session
- ❖Jun 16, 6:45 AMnewsvia finnhub
If You Invested $100 In McKesson Stock 5 Years Ago, You Would Have This Much Today
- ❖Jun 15, 3:14 AMnewsvia finnhub
Is McKesson’s New US$2.25 Billion Term Loan Reshaping the Investment Case for MCK?
Earlier in June 2026, McKesson amended its credit agreement to add a US$2.25 billion senior secured term B loan maturing in 2032, choosing a floating rate based on the Adjusted Term SOFR benchmark plus a margin to support liquidity and operational needs. This financing shift, coming soon after a revenue shortfall, an investment in the Medical-Surgical Solutions unit and increased CEO pay, highlights how capital structure, portfolio moves and governance decisions are all under close investor...
- ❖Jun 13, 1:13 PMnewsvia finnhub
Barclays Maintains Overweight Rating on McKesson (MCK)
McKesson Corporation (NYSE:MCK) is one of the Top 10 Strong Buy Stocks to Invest In. On June 10, 2026, Barclays lowered the firm’s price target on McKesson Corporation (NYSE:MCK) to $925 from $1,050 and maintained an Overweight rating on the shares. Barclays updated estimates and targets in the drug distributor space following recent results. The […]
- !Jun 11, 1:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 1:33 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 1:17 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 12:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 12:33 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 12:17 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 11:47 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 11:34 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 11:19 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 10:47 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 10:33 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 10:18 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 9:47 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 9:34 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 9:16 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 9:05 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 11, 7:03 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 10, 6:04 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 10, 5:45 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 10, 5:30 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 10, 5:15 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 10, 5:01 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 10, 4:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 10, 4:31 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 10, 4:17 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 10, 4:03 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 10, 3:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 10, 3:31 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 10, 3:16 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- ❖Jun 10, 9:00 AMnewsvia finnhub
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- ❖Jun 10, 6:32 AMnewsvia finnhub
Barclays Maintains Overweight on McKesson, Lowers Price Target to $925
Barclays analyst Glen Santangelo maintains McKesson (NYSE:MCK) with a Overweight and lowers the price target from $1050 to $925.
- ❖Jun 9, 11:05 AMnewsvia finnhub
2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now
Italian healthcare vials and cartridges maker Stevanato Group and U.S. generic and wholesale pharmaceutical company Cencora are two of the best healthcare buys right now.
- ❖Jun 8, 1:12 PMnewsvia finnhub
Tris Pharma Introduces a New 60 mL Bottle Size for DYANAVEL® XR (amphetamine) Extended-Release Oral Suspension CII
A new, smaller 60 mL bottle brings pharmacy-stocking and dosing convenience to a once-daily liquid amphetamine designed for individualized titration in ADHDMONMOUTH JUNCTION, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company advancing transformative targeted CNS therapeutics, today announced the availability of DYANAVEL® XR (amphetamine) extended-release oral suspension, CII (2.5 mg/mL) in a new, smaller 60 mL bottle (NDC 24478-102-02)
- ❖Jun 8, 12:15 PMnewsvia finnhub
Here's How Much $100 Invested In McKesson 20 Years Ago Would Be Worth Today
- ❖Jun 6, 10:09 AMnewsvia finnhub
McKesson (MCK) Valuation Check After Recent Share Price Rebound And Mixed Fundamental Signals
McKesson stock reaction and recent performance snapshot McKesson (MCK) has drawn investor attention after recent price moves, with the stock up about 4% over the past week and about 4% over the past month, despite a roughly 16% decline over the past 3 months. Against this backdrop, the share price recently closed at US$775.66. The company reported revenue of US$403.43b and net income of US$4.76b, giving investors a large, established healthcare distributor to assess. See our latest analysis...
- ❖Jun 5, 6:06 PMnewsvia finnhub
Here is What Analysts Are Saying About McKesson Corporation (MCK)
McKesson Corporation (NYSE:MCK) is one of top cheap stocks with Strong Buy ratings on Wall Street. Citi cut the price target on McKesson Corporation (NYSE:MCK) to $945 from $975 on May 14 and reiterated a Buy rating on the shares. The company also received a rating update from BofA on May 8, with the firm […]
- ?Jun 5, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.52 cash available; close=$756.95.
- ?Jun 5, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distribution company with generally solid fundamentals; the 15% drop from the 30-day high lacks any visible fundamental catalyst (no news, no SEC filings, no insider activity in the window), suggesting the decline may be macro/sector-driven rather than company-specific impairment. However, the sector context is modestly negative (Health Care underperforming SPY by ~5.86pts over 30 days, today's sector flow proxy deeply negative), indicating MCK is caught in a broader sector-wide sell-off with limited near-term recovery catalysts. The options flow shows highly unusual put volume (z=5.58) on the most recent trading day with a near-parity P/C ratio, which is a meaningful caution signal even if some of it is hedging rather than directional bearishness.
- ?Jun 4, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.53 cash available; close=$756.95.
- ?Jun 4, 6:03 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distribution company with generally solid fundamentals; the 15% drop from the 30-day high lacks any visible fundamental catalyst (no news, no SEC filings, no insider activity in the window), suggesting the decline may be macro/sector-driven rather than company-specific impairment. However, the sector context is modestly negative (Health Care underperforming SPY by ~5.86pts over 30 days, today's sector flow proxy deeply negative), indicating MCK is caught in a broader sector-wide sell-off with limited near-term recovery catalysts. The options flow shows highly unusual put volume (z=5.58) on the most recent trading day with a near-parity P/C ratio, which is a meaningful caution signal even if some of it is hedging rather than directional bearishness.
- ❖Jun 4, 4:37 PMnewsvia finnhub
3 Cash-Producing Stocks with Promising Prospects
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.
- ❖Jun 4, 9:14 AMnewsvia finnhub
JP Morgan’s Analyst Focus List for June Has 5 Top Passive Income Dividend Picks
All the major Wall Street firms we cover here at 24/7 Wall St. have a list of the top stock picks for their institutional and retail clients to invest in. Typically, these are companies that analysts have a high level of conviction in and feel strongly about their fundamentals and forward-looking prospects. In addition, they ... JP Morgan’s Analyst Focus List for June Has 5 Top Passive Income Dividend Picks
- ?Jun 4, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distribution company with generally solid fundamentals; the 15% drop from the 30-day high lacks any visible fundamental catalyst (no news, no SEC filings, no insider activity in the window), suggesting the decline may be macro/sector-driven rather than company-specific impairment. However, the sector context is modestly negative (Health Care underperforming SPY by ~5.86pts over 30 days, today's sector flow proxy deeply negative), indicating MCK is caught in a broader sector-wide sell-off with limited near-term recovery catalysts. The options flow shows highly unusual put volume (z=5.58) on the most recent trading day with a near-parity P/C ratio, which is a meaningful caution signal even if some of it is hedging rather than directional bearishness.
- ?Jun 4, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.80 cash available; close=$739.53.
- ❖Jun 3, 6:54 PMnewsvia finnhub
McKesson Unit Prices $2.25 Billion Leveraged Loan Ahead of IPO
(Bloomberg) -- A $2.25 billion leveraged loan for McKesson Corp.’s medical-surgical unit priced on Wednesday, ahead of its planned initial public offering.Most Read from BloombergTrump Begins Rebuilding His Tariff Wall, Citing Forced LaborTrump to Get Audit Immunity as $1.8 Billion Fund in DoubtRussia Finance Officials Tell Putin War Spending Is UnaffordableRepublican-Led House Votes to Stop Iran War, Rebuking TrumpTikTok Billionaire Overtakes Mukesh Ambani as Asia’s Second-Richest PersonThe six
- ?Jun 3, 6:06 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distribution company with generally solid fundamentals; the 15% drop from the 30-day high lacks any visible fundamental catalyst (no news, no SEC filings, no insider activity in the window), suggesting the decline may be macro/sector-driven rather than company-specific impairment. However, the sector context is modestly negative (Health Care underperforming SPY by ~5.86pts over 30 days, today's sector flow proxy deeply negative), indicating MCK is caught in a broader sector-wide sell-off with limited near-term recovery catalysts. The options flow shows highly unusual put volume (z=5.58) on the most recent trading day with a near-parity P/C ratio, which is a meaningful caution signal even if some of it is hedging rather than directional bearishness.
- ?Jun 3, 6:05 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.84 cash available; close=$739.95.
- ❖Jun 3, 11:59 AMnewsvia finnhub
Amazon Ends Walmart's 13‑Year Hold On The S&P 500 Revenue Crown — But There's A Catch
The battle between Amazon.com and Walmart has produced a new leader for the Fortune 500 list for 2025 revenue.
- ❖Jun 3, 10:00 AMnewsvia finnhub
We Ran A Stock Scan For Earnings Growth And McKesson (NYSE:MCK) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
- ❖Jun 3, 7:05 AMnewsvia finnhub
Is McKesson Stock Underperforming the Dow?
McKesson has underperformed the Dow over the past year, but analysts are highly optimistic about the stock’s prospects.
- ?Jun 3, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.42 cash available; close=$736.78.
- ?Jun 3, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distribution company with generally solid fundamentals; the 15% drop from the 30-day high lacks any visible fundamental catalyst (no news, no SEC filings, no insider activity in the window), suggesting the decline may be macro/sector-driven rather than company-specific impairment. However, the sector context is modestly negative (Health Care underperforming SPY by ~5.86pts over 30 days, today's sector flow proxy deeply negative), indicating MCK is caught in a broader sector-wide sell-off with limited near-term recovery catalysts. The options flow shows highly unusual put volume (z=5.58) on the most recent trading day with a near-parity P/C ratio, which is a meaningful caution signal even if some of it is hedging rather than directional bearishness.
- ❖Jun 3, 6:03 AMnewsvia finnhub
Texas is the new capital of the Fortune 500—taking California’s crown
The Lone Star State is now home to 57 Fortune 500 companies.
- ?Jun 2, 6:04 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distribution company with generally solid fundamentals; the 15% drop from the 30-day high lacks any visible fundamental catalyst (no news, no SEC filings, no insider activity in the window), suggesting the decline may be macro/sector-driven rather than company-specific impairment. However, the sector context is modestly negative (Health Care underperforming SPY by ~5.86pts over 30 days, today's sector flow proxy deeply negative), indicating MCK is caught in a broader sector-wide sell-off with limited near-term recovery catalysts. The options flow shows highly unusual put volume (z=5.58) on the most recent trading day with a near-parity P/C ratio, which is a meaningful caution signal even if some of it is hedging rather than directional bearishness.
- ❖Jun 2, 8:00 AMnewsvia finnhub
McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions
IRVING, Texas, June 02, 2026--McKesson Corporation (NYSE: MCK) announced today the successful completion of the previously announced minority ownership interest investment from funds managed by affiliates of Apollo ("Apollo Funds") in McKesson’s Medical-Surgical Solutions ("MMS") business on June 1, 2026. This transaction represents a key milestone in McKesson’s intention to separate MMS into an independent, publicly traded company, and positions the business for long-term growth.
- ?Jun 2, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.04 cash available; close=$734.82.
- ?Jun 2, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distribution company with generally solid fundamentals; the 15% drop from the 30-day high lacks any visible fundamental catalyst (no news, no SEC filings, no insider activity in the window), suggesting the decline may be macro/sector-driven rather than company-specific impairment. However, the sector context is modestly negative (Health Care underperforming SPY by ~5.86pts over 30 days, today's sector flow proxy deeply negative), indicating MCK is caught in a broader sector-wide sell-off with limited near-term recovery catalysts. The options flow shows highly unusual put volume (z=5.58) on the most recent trading day with a near-parity P/C ratio, which is a meaningful caution signal even if some of it is hedging rather than directional bearishness.
- ❖Jun 2, 4:14 AMnewsvia finnhub
McKesson Announces Completion Of Previously-Announced $1.25B Minority Ownership Investment By Apollo Funds For 13% Of MCK Subsidiary Medical-Surgical Solutions
Apollo Funds invested $1.25 billion in convertible preferred equity of MMS to acquire an approximately 13% interest in MMS. The transaction values MMS at approximately $13 billion total enterprise valuation. McKesson
- ?Jun 1, 6:04 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distribution company with generally solid fundamentals; the 15% drop from the 30-day high lacks any visible fundamental catalyst (no news, no SEC filings, no insider activity in the window), suggesting the decline may be macro/sector-driven rather than company-specific impairment. However, the sector context is modestly negative (Health Care underperforming SPY by ~5.86pts over 30 days, today's sector flow proxy deeply negative), indicating MCK is caught in a broader sector-wide sell-off with limited near-term recovery catalysts. The options flow shows highly unusual put volume (z=5.58) on the most recent trading day with a near-parity P/C ratio, which is a meaningful caution signal even if some of it is hedging rather than directional bearishness.
- ?Jun 1, 6:03 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.27 cash available; close=$735.70.
- ❖Jun 1, 2:39 PMnewsvia finnhub
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.
- ?Jun 1, 9:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
MCK is down ~1.92% mid-session with 375 minutes (over 6 hours) remaining, suggesting this is early in the session with ample time for the move to continue or reverse. The move is meaningful but not extreme — it represents real selling pressure but hasn't reached the 2-5% threshold that would signal strong conviction. No headlines are available to explain the catalyst, which is neutral per guidance. The macro context (T10Y3M elevated at 1.6σ above trend) is flagged as relevant to Banks and recession-sensitive sectors; MCK is a healthcare distribution company, not directly in those sectors, so macro headwinds are modest and indirect at best. With no news driver, no clear reversal pattern described, and substantial time remaining, the base case is mild momentum continuation. However, the absence of a clear catalyst and the relatively modest decline (under 2%) leave this as a low-conviction setup. Assigning a slight lean toward continuation given the meaningful selling flow and ample time remaining, but probability stays near the floor given the weak evidence base.
- ?Jun 1, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $29.62 cash available; close=$742.44.
- ?Jun 1, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distribution company with generally solid fundamentals; the 15% drop from the 30-day high lacks any visible fundamental catalyst (no news, no SEC filings, no insider activity in the window), suggesting the decline may be macro/sector-driven rather than company-specific impairment. However, the sector context is modestly negative (Health Care underperforming SPY by ~5.86pts over 30 days, today's sector flow proxy deeply negative), indicating MCK is caught in a broader sector-wide sell-off with limited near-term recovery catalysts. The options flow shows highly unusual put volume (z=5.58) on the most recent trading day with a near-parity P/C ratio, which is a meaningful caution signal even if some of it is hedging rather than directional bearishness.
- ?May 29, 6:03 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $735.32 cash available; close=$742.94.
- ❖May 29, 8:00 AMnewsvia finnhub
Research Presented by The US Oncology Network Demonstrates How Community Practices Are Expanding Patient Access Through APP‑Led Models at ASCO 2026
THE WOODLANDS, Texas, May 29, 2026--Research presented by The US Oncology Network found that new patient consult models led by advanced practice providers can accelerate access to care.
- ?May 29, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.04 cash available; close=$756.98.
- ?May 29, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $9.19 cash available; close=$756.98.
- ?May 28, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $12.25 cash available; close=$756.47.
- ?May 28, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $6.30 cash available; close=$756.47.
- ❖May 28, 5:05 PMnewsvia finnhub
Top gainers and losers in the S&P500 index during Thursday's after-hours session.
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.
- ❖May 28, 5:00 PMnewsvia finnhub
Stay updated with the stocks that are on the move in today's after-hours session.
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
- ?May 28, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.29 cash available; close=$756.47.
- ?May 28, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $8.03 cash available; close=$756.47.
- ?May 27, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$754.40.
- ?May 27, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $9.46 cash available; close=$754.40.
- ❖May 27, 11:16 AMnewsvia finnhub
Baron Health Care Fund Q1 2026 Portfolio Activity
During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41.
- ❖May 27, 9:00 AMnewsvia finnhub
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
- ?May 27, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$754.40.
- ?May 27, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $21.36 cash available; close=$754.40.
- ❖May 27, 7:00 AMnewsvia finnhub
Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy
Nanoscope Therapeutics Inc., a biotechnology company focused on developing and commercializing novel, disease‑agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that it has selected InspiroGene by McKesson to provide U.S. commercialization services for its lead product, MOGENRY™, subject to U.S. regulatory approval.
- ?May 26, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $22.31 cash available; close=$766.08.
- ?May 26, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $2.08 cash available; close=$766.08.
- ?May 26, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$766.08.
- ?May 26, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$766.08.
- ❖May 25, 6:45 AMnewsvia finnhub
$1000 Invested In McKesson 5 Years Ago Would Be Worth This Much Today
- ?May 22, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $5.71 cash available; close=$766.50.
- ?May 22, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distributor with historically durable cash flows and a strong business model, so the underlying company is financially sound. The 13.5% drop from the 30-day high appears to be sector-driven rather than company-specific, as Health Care (XLV) is the second-weakest sector on 30-day relative strength (-13.87pts vs SPY), suggesting MCK was caught in a broad healthcare selloff. However, there are no confirmation signals — no insider buying, no unusual call flow, no analyst upgrades, and no upcoming catalyst — leaving the thesis as a pure mean-reversion play on a fundamentally solid name.
- ❖May 22, 5:11 PMnewsvia finnhub
Dividend Champion, Contender, And Challenger Highlights: Week Of May 24
Get this weekly dividend update on Champions, Contenders & Challengersâsee dividend changes, upcoming ex-dividend dates and pay dates.
- ❖May 22, 3:08 PMnewsvia finnhub
A Look Back at Healthcare Providers & Services Stocks’ Q1 Earnings: McKesson (NYSE:MCK) Vs The Rest Of The Pack
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at McKesson (NYSE:MCK) and its peers.
- ❖May 22, 12:16 PMnewsvia finnhub
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.
- ❖May 22, 10:13 AMnewsvia finnhub
TBRG Posts Q1 Earnings: How to Play the Stock Amid Pending Sell-off?
TruBridge climbs after Q1 EPS beats estimates and an IKS Health buyout deal sets a $26.25-per-share cash offer for shareholders.
- ❖May 22, 9:44 AMnewsvia finnhub
Are Wall Street Analysts Predicting McKesson Stock Will Climb or Sink?
McKesson has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.
- ?May 22, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$766.50.
- ?May 22, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distributor with historically durable cash flows and a strong business model, so the underlying company is financially sound. The 13.5% drop from the 30-day high appears to be sector-driven rather than company-specific, as Health Care (XLV) is the second-weakest sector on 30-day relative strength (-13.87pts vs SPY), suggesting MCK was caught in a broad healthcare selloff. However, there are no confirmation signals — no insider buying, no unusual call flow, no analyst upgrades, and no upcoming catalyst — leaving the thesis as a pure mean-reversion play on a fundamentally solid name.
- ?May 21, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$754.68.
- ?May 21, 6:00 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distributor with historically durable cash flows and a strong business model, so the underlying company is financially sound. The 13.5% drop from the 30-day high appears to be sector-driven rather than company-specific, as Health Care (XLV) is the second-weakest sector on 30-day relative strength (-13.87pts vs SPY), suggesting MCK was caught in a broad healthcare selloff. However, there are no confirmation signals — no insider buying, no unusual call flow, no analyst upgrades, and no upcoming catalyst — leaving the thesis as a pure mean-reversion play on a fundamentally solid name.
- ?May 21, 11:47 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$754.68.
- ?May 21, 11:46 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distributor with historically durable cash flows and a strong business model, so the underlying company is financially sound. The 13.5% drop from the 30-day high appears to be sector-driven rather than company-specific, as Health Care (XLV) is the second-weakest sector on 30-day relative strength (-13.87pts vs SPY), suggesting MCK was caught in a broad healthcare selloff. However, there are no confirmation signals — no insider buying, no unusual call flow, no analyst upgrades, and no upcoming catalyst — leaving the thesis as a pure mean-reversion play on a fundamentally solid name.
- ?May 21, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distributor with historically durable cash flows and a strong business model, so the underlying company is financially sound. The 13.5% drop from the 30-day high appears to be sector-driven rather than company-specific, as Health Care (XLV) is the second-weakest sector on 30-day relative strength (-13.87pts vs SPY), suggesting MCK was caught in a broad healthcare selloff. However, there are no confirmation signals — no insider buying, no unusual call flow, no analyst upgrades, and no upcoming catalyst — leaving the thesis as a pure mean-reversion play on a fundamentally solid name.
- ?May 21, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$754.68.
- ?May 20, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$761.89.
- ?May 20, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distributor with historically durable cash flows and a strong business model, so the underlying company is financially sound. The 13.5% drop from the 30-day high appears to be sector-driven rather than company-specific, as Health Care (XLV) is the second-weakest sector on 30-day relative strength (-13.87pts vs SPY), suggesting MCK was caught in a broad healthcare selloff. However, there are no confirmation signals — no insider buying, no unusual call flow, no analyst upgrades, and no upcoming catalyst — leaving the thesis as a pure mean-reversion play on a fundamentally solid name.
- ?May 20, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distributor with historically durable cash flows and a strong business model, so the underlying company is financially sound. The 13.5% drop from the 30-day high appears to be sector-driven rather than company-specific, as Health Care (XLV) is the second-weakest sector on 30-day relative strength (-13.87pts vs SPY), suggesting MCK was caught in a broad healthcare selloff. However, there are no confirmation signals — no insider buying, no unusual call flow, no analyst upgrades, and no upcoming catalyst — leaving the thesis as a pure mean-reversion play on a fundamentally solid name.
- ?May 20, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$761.89.
- ?May 19, 6:02 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$775.97.
- ?May 19, 6:02 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
MCK (McKesson) is a large-cap healthcare distributor with historically durable cash flows and a strong business model, so the underlying company is financially sound. The 13.5% drop from the 30-day high appears to be sector-driven rather than company-specific, as Health Care (XLV) is the second-weakest sector on 30-day relative strength (-13.87pts vs SPY), suggesting MCK was caught in a broad healthcare selloff. However, there are no confirmation signals — no insider buying, no unusual call flow, no analyst upgrades, and no upcoming catalyst — leaving the thesis as a pure mean-reversion play on a fundamentally solid name.